Extracorporeal Life Support (ECLS) is a critical medical technology system that replaces or assists failing organ functions through extracorporeal circulation equipment. Its core products cover a full-scenario support system with low, medium and high flow rates, among which ECMO, as a high-flow representative, is widely used in clinical scenarios such as critical care, organ transplantation and cardiopulmonary resuscitation. With the continuous breakthroughs in biocompatible materials and extracorporeal circulation technology, the industry has achieved a leap from simple life maintenance to precise intervention. Equipment is gradually evolving towards portability and intelligence, with more comprehensive monitoring systems to meet the needs of multi-scenario treatment inside and outside hospitals.
Driven by the wave of domestic substitution, domestic enterprises have broken through the technical barriers of core components of ECMO, and complete machines and consumables have been launched one after another, breaking the monopoly of imports. The aging population, the growing demand for critical illness diagnosis and treatment, and policy support such as hierarchical diagnosis and treatment have promoted the rapid expansion of the market scale, and the application scenarios have extended to primary medical care, pre-hospital emergency care and other fields. In the future, the industry will focus on personalized treatment and multi-organ comprehensive support, continuously improve technical standards and training systems, provide safer and more effective life support solutions for critically ill patients around the world, and the market potential will continue to be released.
